Black Rock Inc. Aptevo Therapeutics Inc. Transaction History

Black Rock Inc.

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	SELL	$0.17 - $0.38 $175 - $392	-1,033 Reduced 2.17%	46,635 $8,000
Q3 2023 Nov 13, 2023	SELL	$0.31 - $1.78 $117 - $672	-378 Reduced 0.79%	47,668 $15,000
Q2 2022 Aug 12, 2022	SELL	$3.26 - $6.3 $20,606 - $39,822	-6,321 Reduced 11.63%	48,046 $172,000
Q1 2022 May 12, 2022	SELL	$4.48 - $8.42 $1,370 - $2,576	-306 Reduced 0.56%	54,367 $319,000
Q4 2021 Feb 10, 2022	SELL	$6.48 - $17.49 $4,672 - $12,610	-721 Reduced 1.3%	54,673 $430,000
Q3 2021 Nov 09, 2021	BUY	$15.01 - $22.16 $15,160 - $22,381	1,010 Added 1.86%	55,394 $856,000
Q2 2021 Aug 11, 2021	BUY	$21.85 - $30.0 $1.19 Million - $1.63 Million	54,384 New	54,384 $1.22 Million

Ticker APVO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 5,090,640
Market Cap $24.5M
Description
Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. Its lead clinical candidate is APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelo...

Get notified when there are updates to the investment portfolio of Black Rock Inc., based on Form 13F filings with the SEC.

Stay updated on Black Rock Inc. with notifications on news.